We have located links that may give you full text access.
Cardiac-sparing whole lung imrt in patients with pediatric tumors and lung metastasis: Final report of a prospective multicenter clinical trial.
PURPOSE: A prospective clinical trial was conducted for patients undergoing cardiac sparing (CS) whole lung irradiation (WLI) using IMRT. The 3 trial aims were: 1) To demonstrate the feasibility of CS IMRT with real time central quality control; 2) To determine the dosimetric advantages of WLI using IMRT compared to standard antero-posterior (AP) techniques; and 3) To determine acute tolerance and short-term efficacy after a protocol mandated minimum 2 year follow up for all patients.
METHODS: All patients underwent a 3D chest CT scan and a contrast-enhanced 4D gated chest CT scan using a standard gating device. The CTV was the entire bilateral 3D lung volume and the ITV was the 4D minimum intensity projection of both lungs. The ITV was expanded by 1cm to get the PTV. All target volumes, cardiac contours and treatment plans were centrally reviewed before treatment. The different cardiac volumes (V) receiving percentages (%) of prescribed RT doses on AP and IMRT WLI plans were estimated and compared.
RESULTS: The target 20 patients were accrued in 2 years. Median RT dose was 15Gy. Real time central Quality Assurance review and plan pre-approval was obtained for all patients. WLI using IMRT was feasible in all patients. Compared to standard AP WLI, CS IMRT resulted in statistically significant reduction in radiation doses to the whole heart, atria, ventricles and coronaries. One child developed cardiac dysfunction and pulmonary restrictive disease 5.5 years after CS IMRT (15Gy) and doxorubicin (375mg/m2).The 2 and 3 year lung metastasis progression free survival was 65% and 52% respectively.
CONCLUSIONS: We have demonstrated the feasibility of WLI using CS IMRT and confirmed the previously reported advantages of IMRT including superior cardiac protection and superior dose coverage of 4D lung volumes. Further studies are required to establish the efficacy and safety of this irradiation technique.
METHODS: All patients underwent a 3D chest CT scan and a contrast-enhanced 4D gated chest CT scan using a standard gating device. The CTV was the entire bilateral 3D lung volume and the ITV was the 4D minimum intensity projection of both lungs. The ITV was expanded by 1cm to get the PTV. All target volumes, cardiac contours and treatment plans were centrally reviewed before treatment. The different cardiac volumes (V) receiving percentages (%) of prescribed RT doses on AP and IMRT WLI plans were estimated and compared.
RESULTS: The target 20 patients were accrued in 2 years. Median RT dose was 15Gy. Real time central Quality Assurance review and plan pre-approval was obtained for all patients. WLI using IMRT was feasible in all patients. Compared to standard AP WLI, CS IMRT resulted in statistically significant reduction in radiation doses to the whole heart, atria, ventricles and coronaries. One child developed cardiac dysfunction and pulmonary restrictive disease 5.5 years after CS IMRT (15Gy) and doxorubicin (375mg/m2).The 2 and 3 year lung metastasis progression free survival was 65% and 52% respectively.
CONCLUSIONS: We have demonstrated the feasibility of WLI using CS IMRT and confirmed the previously reported advantages of IMRT including superior cardiac protection and superior dose coverage of 4D lung volumes. Further studies are required to establish the efficacy and safety of this irradiation technique.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
The Effect of Albumin Administration in Critically Ill Patients: A Retrospective Single-Center Analysis.Critical Care Medicine 2024 Februrary 8
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app